Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes
Stephen L. Tilley, … , Thomas M. Coffman, Beverly H. Koller
Stephen L. Tilley, … , Thomas M. Coffman, Beverly H. Koller
Published July 1, 2001
Citation Information: J Clin Invest. 2001;108(1):15-23. https://doi.org/10.1172/JCI13416.
View: Text | PDF
Perspective

Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes

  • Text
  • PDF
Abstract

Authors

Stephen L. Tilley, Thomas M. Coffman, Beverly H. Koller

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Potential pro- and anti-inflammatory actions of prostanoids in asthma. (...
Potential pro- and anti-inflammatory actions of prostanoids in asthma. (a) Proinflammatory actions of TXA2 and PGE2. Solid red receptors indicate pathways that enhance airway inflammation. TXA2 activates leukocytes and increases airway obstruction by inducing airway smooth muscle contraction and goblet cell mucus secretion. PGE2 promotes vasodilation by activating cAMP-coupled EP2 receptors on vascular smooth muscle and increases vascular permeability indirectly by enhancing the release of histamine and other mediators from tissue leukocytes such as mast cells. Receptors for which there is insufficient information to define a proinflammatory role are depicted in gray. (b) Anti-inflammatory actions of PGE2. Solid blue receptors indicate pathways that reduce airway inflammation. As inflammation progresses, PGE2 synthesis by macrophages is enhanced due to increased expression of COX-2 and PGE-synthase. PGE2 inhibits leukocyte activation and promotes bronchodilation through activation of Gs-coupled EP2 and EP4 receptors. Increased expression of EP2 receptors is likely to further enhance these anti-inflammatory actions of PGE2. Receptors for which there is insufficient information to define an anti-inflammatory role are depicted in gray. H1, histamine receptor; TP, TXA2 receptor; EP, PGE2 receptor.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts